NVRO

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Nevro Corp

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
CEO
D.Keith Grossman
Employees
843
Headquarters

1800 Bridge Pkwy
Redwood City, California 94065-1164
Phone: 16502510005
www.nevro.com

News

Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series
Feb 23, 2023 21:05pm

Friday, March 24, 2023 at 2:00 pm Eastern Time REDWOOD CITY, Calif., Feb. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman,…


Source:PR Newswire
Nevro falls to 52-week low; down ~49% over last year (NYSE:NVRO)
Feb 22, 2023 19:46pm

Medical device company Nevro (NVRO) hit a 52-week low of $33.36 on Wednesday. Over the last year, the stock is down ~49%.


Source:Seeking Alpha
These strategies will help Nevro Corp. (NVRO) succeed
Feb 17, 2023 13:40pm

Nevro Corp. (NYSE:NVRO) marked $39.51 per share on Thursday, up from a previous closing price of $38.33. While Nevro Corp. has overperformed by 3.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -45.91%, with highs and lows ranging from $78.90 to $34.70, whereas […]


Source:US Post News
Analyst Looks For Improvement Signs For Nevro''s Core Market In 2023 After Mixed Q4 Earnings
Feb 17, 2023 10:51am

Nevro Corp (NYSE: NVRO ) reported Q4 FY22 sales of $113.8 million , up 11% Y/Y as reported and 12% constant currency, beating the consensus of $113.40 million. Painful diabetic neuropathy (PDN) indication sales of approximately $17.3 million grew 329%, bringing the first full-year sales to approximately $48.0 million. Q4 FY22 U.S. trial procedures increased by 9%, while U.S. PDN trial procedures grew to 20% of total U.S. trials in the quarter. Guidance: Nevro expects Q1 FY23 sales of $94-$96 million vs. the consensus of $97.51 million. PDN indication Q1 sales … Full story available on Benzinga.com


Source:Benzinga
Nevro Corporation (NVRO) Q4 2022 Earnings Call Transcript
Feb 17, 2023 03:07am

Nevro Corporation (NYSE:NYSE:NVRO) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ETCompany ParticipantsJulie Dewey - Chief Corporate Communications and Investor Relations…


Source:Seeking Alpha
Nevro: Q4 Earnings Snapshot
Feb 16, 2023 22:12pm

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Thursday reported a loss of $19.2…


Source:WTOP
Nevro GAAP EPS of -$0.54 misses by $0.05, revenue of $113.84M beats by $0.14M
Feb 16, 2023 21:22pm

Nevro press release (NVRO): Q4 GAAP EPS of -$0.54 misses by $0.05.Revenue of $113.84M (+10.8% Y/Y) beats by $0.14M.Provides First Quarter 2023 Revenue Guidance of $94 Million to…


Source:Seeking Alpha
Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
Feb 16, 2023 21:05pm

REDWOOD CITY, Calif., Feb. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its fourth quarter and full-year 2022 financial results. The company…


Source:PR Newswire
Earnings Preview For Nevro
Feb 15, 2023 18:01pm

Nevro (NYSE: NVRO ) is set to give its latest quarterly earnings report on Thursday, 2023-02-16. Here''s what investors need to know before the announcement. Analysts estimate that Nevro will report an earnings per share (EPS) of $-0.49. Nevro bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com


Source:Benzinga
Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains
Feb 14, 2023 16:11pm

Nevro Corp. has seen multiple boom-bust cycles in its share price, and we are in the bust phase again. Does this mean NVRO stock is a buy? Read to find out.


Source:Seeking Alpha
Was anything negative for Nevro Corp. (NVRO) stock last session?
Feb 09, 2023 16:24pm

The share price of Nevro Corp. (NYSE:NVRO) fell to $37.35 per share on Wednesday from $38.58. While Nevro Corp. has underperformed by -3.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -42.39%, with highs and lows ranging from $78.90 to $34.70, whereas the […]


Source:US Post News
Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year
Jan 31, 2023 21:05pm

Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies REDWOOD CITY, Calif., Jan. 31, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of…


Source:PR Newswire
Nevro Corp PT Lowered to $37 at Piper Sandler
Jan 26, 2023 11:43am

https://www.investing.com/news/pro/nevro-corp-pt-lowered-to-37-at-piper-sandler-432SI-2988659


Source:Investing.com